Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MGX Metagenomi	$1.86 -2.1%	$1.89	$1.23 ▼ $4.92	$69.81M	-0.12	631,177 shs	227,602 shs
OTLK Oncobiologics	$2.34 -3.7%	$1.94	$0.87 ▼ $8.32	$78.55M	0.26	1.03 million shs	2.68 million shs
PIRS Pieris Pharmaceuticals	$13.60	$15.17	$12.63 ▼ $18.68	$17.95M	0.61	90,136 shs	51,728 shs
ZIVO ZIVO Bioscience	$18.25 +0.2%	$13.73	$6.50 ▼ $22.15	$69.66M	-0.06	1,059 shs	2,556 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MGX Metagenomi	0.00%	-3.12%	-12.68%	+12.05%	-40.00%
OTLK Oncobiologics	0.00%	+23.16%	+1.30%	+33.71%	-68.12%
PIRS Pieris Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-18.81%
ZIVO ZIVO Bioscience	0.00%	+25.95%	+37.74%	+1.39%	+112.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MGX Metagenomi	2.5899 of 5 stars	3.5	2.0	0.0	0.0	2.8	1.7	0.6
OTLK Oncobiologics	1.8276 of 5 stars	3.4	2.0	0.0	0.0	2.2	0.0	0.6
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	0.2479 of 5 stars	0.0	3.0	0.0	0.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MGX Metagenomi	3.00	Buy	$10.00	437.63% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	310.26% Upside
PIRS Pieris Pharmaceuticals	0.00	N/A	N/A	N/A
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PIRS, OTLK, ZIVO, and MGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/15/2025	OTLK Oncobiologics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00
8/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MGX Metagenomi	$33.77M	2.07	N/A	N/A	$5.22 per share	0.36
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A
PIRS Pieris Pharmaceuticals	$42.81M	0.42	N/A	N/A	$21.66 per share	0.63
ZIVO ZIVO Bioscience	$15.85K	4,394.97	N/A	N/A	($0.81) per share	-22.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MGX Metagenomi	-$78.06M	-$2.36	N/A	N/A	N/A	-257.99%	-37.84%	-27.15%	N/A
OTLK Oncobiologics	-$75.37M	-$0.57	N/A	N/A	N/A	N/A	N/A	-335.21%	N/A
PIRS Pieris Pharmaceuticals	-$24.54M	-$12.10	N/A	∞	N/A	-39.71%	-80.93%	-59.55%	N/A
ZIVO ZIVO Bioscience	-$7.78M	-$4.93	N/A	∞	N/A	N/A	N/A	-2,240.92%	N/A

Latest PIRS, OTLK, ZIVO, and MGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q3 2025	OTLK Oncobiologics	-$0.42	-$0.44	-$0.02	-$0.55	$1.66 million	$1.51 million
8/12/2025	Q2 2025	MGX Metagenomi	-$0.68	-$0.54	+$0.14	-$0.54	$7.72 million	$8.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
PIRS Pieris Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MGX Metagenomi	N/A	6.36	5.85
OTLK Oncobiologics	N/A	0.72	0.57
PIRS Pieris Pharmaceuticals	N/A	4.82	4.82
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MGX Metagenomi	N/A
OTLK Oncobiologics	11.20%
PIRS Pieris Pharmaceuticals	40.11%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
MGX Metagenomi	17.80%
OTLK Oncobiologics	4.80%
PIRS Pieris Pharmaceuticals	6.39%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MGX Metagenomi	236	37.53 million	30.85 million	N/A
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable
PIRS Pieris Pharmaceuticals	140	1.32 million	1.24 million	Optionable
ZIVO ZIVO Bioscience	10	3.82 million	2.91 million	Not Optionable

PIRS, OTLK, ZIVO, and MGX Headlines

Recent News About These Companies

Analyzing ZIVO Bioscience (NASDAQ:ZIVO) & Protalix BioTherapeutics (NYSE:PLX)

August 15 at 3:39 AM | americanbankingnews.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIRS, OTLK, ZIVO, and MGX Company Descriptions

Metagenomi NASDAQ:MGX

$1.86 -0.04 (-2.11%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.90 +0.04 (+2.42%)

As of 08/15/2025 07:49 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Oncobiologics NASDAQ:OTLK

$2.34 -0.09 (-3.70%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.08 (+3.42%)

As of 08/15/2025 07:49 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Pieris Pharmaceuticals NASDAQ:PIRS

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

ZIVO Bioscience NASDAQ:ZIVO

$18.25 +0.03 (+0.16%)

As of 08/15/2025 03:57 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time